Rossari Biotech Share Price

Intimation of Transcript of Q2 & H1 FY27 for the Earnings Conference Call held on October 19, 2026

• BSE India
• 4 days 1 hour ago

Audio recording of Earnings Conference Call for Q2 & H1 FY 27.

• BSE India
• 1 week ago

<h3><span style="font-size:16px;"><strong>Specialty Chemicals company Rossari Biotech announced Q2FY27 results</strong></span></h3> <p _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Revenue from operations:</strong> Reached Rs 4,952.76 million in 'Q2FY27', representing an 18.06% YoY increase from Rs 4,195.12 million in 'Q2FY26', and a 2.70% QoQ growth from Rs 4,822.75 million in 'Q1FY27'.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Total Income:</strong> Stood at Rs 4,969.62 million in 'Q2FY27', reflecting a YoY increase of 18.07% from Rs 4,209.09 million in 'Q2FY26', and a QoQ rise of 2.58% from Rs 4,844.63 million in 'Q1FY27'.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Profit before Tax:</strong> Recorded at Rs 461.53 million in 'Q2FY27', indicating a 9.96% YoY growth from Rs 419.72 million in 'Q2FY26', but a marginal QoQ decline of 0.58% from Rs 464.21 million in 'Q1FY27'.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Net Profit after Tax (PAT):</strong> Achieved Rs 342.31 million in 'Q2FY27', marking a 9.54% YoY increase from Rs 312.49 million in 'Q2FY26', and a slight QoQ decrease of 0.10% from Rs 342.66 million in 'Q1FY27'. For 'H1FY27', PAT stood at Rs 684.97 million.</li> </ul> <p _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Revenue from operations:</strong> Reached Rs 6,975.60 million in 'Q2FY27', demonstrating a YoY growth of 19.02% from Rs 5,861.07 million in 'Q2FY26', and remaining relatively flat QoQ with a 0.05% increase from Rs 6,972.00 million in 'Q1FY27'.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Total Income:</strong> Stood at Rs 6,981.59 million in 'Q2FY27', showing an 18.79% YoY increase from Rs 5,877.11 million in 'Q2FY26', and a QoQ drop of 0.32% from Rs 7,003.87 million in 'Q1FY27'.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Profit before Tax:</strong> Recorded at Rs 492.69 million in 'Q2FY27', representing a slight YoY decline of 0.81% from Rs 496.72 million in 'Q2FY26', but a 3.35% QoQ increase from Rs 476.72 million in 'Q1FY27'.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Net Profit after Tax (PAT):</strong> Achieved Rs 389.07 million in 'Q2FY27', reflecting a 5.51% YoY growth from Rs 368.76 million in 'Q2FY26', and a QoQ increase of 10.86% from Rs 350.95 million in 'Q1FY27'. For 'H1FY27', consolidated PAT reached Rs 740.02 million.</li> </ul> <p _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Greenfield Expansion:</strong> The Board accorded its approval for the leasing of land by Rossari International Limited Company, a wholly-owned subsidiary, to set up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA).</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Stock Options:</strong> During the quarter ended September 30, 2026, the Parent Company allotted 2,500 equity shares of Rs 2 each pursuant to the exercise of options under the approved Rossari Employee Stock Option Plan - 2019.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Segment Reporting:</strong> The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.</li> </ul> <p><strong>Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said:</strong> “We delivered robust consolidated growth of 19% YoY in Q2FY27, achieving a record quarterly revenue of Rs 698 crore. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. We concluded the first half of FY27 on a strong note, with consolidated revenue of Rs 1,395 crore in H1FY27, a healthy growth of 23% YoY. The growth was broad-based, led by healthy volume, improved product mix and focused execution across our businesses. During Q2FY27, the HPPC, TSC and AHN businesses delivered YoY growth of 18%, 26% and 11%, respectively. Performance was supported by a higher contribution from value-added products and improved wallet share with customers across end-user industries.</p> <p>We continue to operate under dynamic business environment marked by raw material volatility, geopolitical uncertainty and cautious customer behaviour. Despite of these headwinds in Q2FY27 we maintained the gross margin at ~32% level and EBITDA margin at ~12.5% level.</p> <p>During H1FY27, we made progress in strengthening our balance sheet and improving cash flow generation. Our net working capital cycle improved to 86 days as of 30 September 2026, compared with 97 days as of 31 March 2026. Further, net debt declined to Rs 221 crore from Rs 281 crore over the same period.</p> <p>We are pleased to announce that the Board has approved the leasing of land to Rossari International Limited Company (RILC), our wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This builds on the in-principle approval granted by the Board earlier and marks a key milestone in Rossari’s international growth journey.</p> <p>Our strategic initiatives are progressing in the right direction. These include monetising non-core assets, rationalising lower-margin businesses and improving the product mix. We remain confident that operating leverage, scale benefits and these initiatives will support progressive improvement in profitability. With strong R&D capabilities, expanding capacities, a healthy balance sheet and a growing global footprint, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained long-term growth.”</p> <p><a class="lb" href="/get-document/post/pdf/5901711/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 week ago